238 related articles for article (PubMed ID: 34654390)
41. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
Yin K; Feng HB; Li LL; Chen Y; Xie Z; Lv ZY; Guo WB; Lu DX; Yang XN; Yan WQ; Wu YL; Zhang XC
Thorac Cancer; 2020 Feb; 11(2):346-352. PubMed ID: 31794146
[TBL] [Abstract][Full Text] [Related]
42. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
[TBL] [Abstract][Full Text] [Related]
43. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K
Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094
[TBL] [Abstract][Full Text] [Related]
44. Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.
Ishii H; Azuma K; Sakai K; Naito Y; Matsuo N; Tokito T; Yamada K; Hoshino T; Nishio K
Sci Rep; 2020 Jan; 10(1):691. PubMed ID: 31959859
[TBL] [Abstract][Full Text] [Related]
45. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
46. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
47. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
48. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
Yamamoto N; Mera T; Märten A; Hochmair MJ
Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283
[TBL] [Abstract][Full Text] [Related]
49. Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
Zhang B; Xu J; Zhang X; Gu P; Wang H; Wang S; Qian J; Qiao R; Zhang Y; Yang W; Qian F; Zhou Y; Lu J; Zhang L; Han B
Lung Cancer; 2018 Mar; 117():27-31. PubMed ID: 29496252
[TBL] [Abstract][Full Text] [Related]
50. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.
Hu W; Liu Y; Chen J
Oncotarget; 2017 Apr; 8(15):25046-25054. PubMed ID: 28212572
[TBL] [Abstract][Full Text] [Related]
51. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S
J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
Wang X; Zeng Z; Cai J; Xu P; Liang P; Luo Y; Liu A
BMC Cancer; 2021 Apr; 21(1):482. PubMed ID: 33931014
[TBL] [Abstract][Full Text] [Related]
53. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
54. Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
Wang Y; Zheng R; Hu P; Zhang Z; Shen S; Li X
BMC Cancer; 2021 Nov; 21(1):1215. PubMed ID: 34774017
[TBL] [Abstract][Full Text] [Related]
55. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
56. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
57. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
Vaid AK; Gupta A; Momi G
Int J Oncol; 2021 Feb; 58(2):171-184. PubMed ID: 33491758
[TBL] [Abstract][Full Text] [Related]
58. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in
Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV
Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210
[TBL] [Abstract][Full Text] [Related]
59. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
60. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.
Chevallier M; Tsantoulis P; Addeo A; Friedlaender A
Cancer Genomics Proteomics; 2020; 17(5):597-603. PubMed ID: 32859638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]